AstraZeneca set to strike drug pricing deal with Trump

What's new in pharma

October 10, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

HECTOR RETAMAL/AFP via Getty Images STAT+ | AstraZeneca set to strike drug pricing deal with Trump More details of the agreement between Trump and U.K.-based AstraZeneca are set to be shared at the White House this evening. By Daniel Payne STAT+ | Roche suffers setback as court allows generic version of its rare disease drug to be sold in India Roche has sought to prevent a generics company from proceeding with plans to make a version of a spinal muscular atrophy therapy. By Ed Silverman STAT+ | Canadian lawmakers urge the government to suspend imports of long-tailed macaques The demand occurs amid an ongoing scandal involving shipments of the monkeys to the U.S. and Canada over the past two year. By Ed Silverman Adobe STAT+ | Bristol Myers to buy startup Orbital Therapeutics, building out cell therapy pipeline Orbital has been developing in vivo CAR-T treatments that could make it easier to use cell therapies to treat autoimmune disorders. By Jason Mast STAT+ | Senate-passed BIOSECURE Act would add arrow to Trump's drug-pricing quiver The legislation would restrict U.S. pharmaceutical and biotechnology companies from doing business with certain Chinese companies. By John Wilkerson STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser